The Pharma Data

MARCH 11, 2021

Sustainability forms an integral part of Bayer’s business strategy, growth plans and incentive systems, Baumann stressed, citing as an example the company’s decision to become carbon-neutral by 2030. Last year alone, the company concluded more than 25 collaboration and licensing agreements and acquisitions in its Pharmaceuticals Division.

Science 52

Science Pharmaceuticals Licensing Licensing 52

The Pharma Data

AUGUST 5, 2021

approval; acquisition of Vividion Therapeutics agreed; start of first clinical study for Parkinson’s cell therapy treatment. Food and Drug Administration for the treatment of adult patients with chronic kidney disease and type 2 diabetes. Group sales increase by 12.9 percent (Fx & portfolio adj.) percent to 1.61

Production 52

Production Pharmaceuticals Science Therapies 52

The Pharma Data

NOVEMBER 5, 2020

Lastly, we are proud that our novel antibody cocktail REGN-EB3 recently became the first FDA-approved treatment for Ebola, underscoring the potential of antibody therapies to address deadly infectious diseases.” ” “We continue to invest in our promising pipeline while delivering meaningful revenue and earnings growth.

Production 40

Production FDA Trials FDA Approval 40

The Pharma Data

JANUARY 9, 2021

Pipeline progress is expected across the vaccines, therapeutics, and devices portfolios, anticipating at least one Phase 3 launch and one Biologics License Application (BLA)/Emergency Use Authorization (EUA) filing. In working together, we envision protecting or enhancing 1 billion lives by 2030. FOOTNOTES. (1)

Government 40

Government Vaccine Production Licensing 40

The Pharma Data

APRIL 27, 2021

Dupixent ® was approved in China for the treatment of adults with moderate-to-severe AD in June 2020 and is listed on the NRDL (National Reimbursement Drug List) as of March 2021. reflecting lower treatment compliance during the COVID-19 pandemic. First-quarter Fabrazyme ® sales increased 4.7% In the U.S. sales decreased 2.9%

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

FEBRUARY 8, 2021

Dupixent ® was approved in China for the treatment of adults with moderate-to-severe AD in June and will be listed on the NRDL (National Reimbursement Drug List) as of March 2021. Fabrazyme ® was launched in China in May and is the first treatment for Fabry disease approved in China. Fourth-quarter Fabrazyme ® sales decreased 0.9%

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

FEBRUARY 4, 2021

Dupixent ® was approved in China for the treatment of adults with moderate-to-severe AD in June and will be listed on the NRDL (National Reimbursement Drug List) as of March 2021. Fabrazyme ® was launched in China in May and is the first treatment for Fabry disease approved in China. Fourth-quarter Fabrazyme ® sales decreased 0.9%

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

NOVEMBER 22, 2020

This patent completes the Ezeprogind related patents granted in the USA for composition of matter (US 9,562,018) and therapeutic uses in the treatment of Alzheimer’s and Parkinson’s diseases (US 10,537,569). The average life expectancy of PSP patients ranges from 5 to 7 years. View source version on businesswire.com: [link].

Drugs 40

Drugs Disease Clinical Trials Licensing 40

Agency IQ

JUNE 16, 2023

Final Rule Stage Clean Water Act Section 401: Water Quality Certification 2040-AG12 August 2023 Clean Water Act (CWA) section 401 provides States and Tribes with a powerful tool to protect the quality of their waters from adverse impacts resulting from federally licensed or permitted projects.

Regulations 40

Regulations Compliance Production Science 40